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ABSTRACT
Objectives To determine the safety and effectiveness 
of home oximetry monitoring pathways for patients with 
COVID-19 in the English National Health Service.
Design Retrospective, multisite, observational study of 
home oximetry monitoring for patients with suspected or 
proven COVID-19.
Setting This study analysed patient data from four 
COVID-19 home oximetry pilot sites in England across 
primary and secondary care settings.
Participants A total of 1338 participants were enrolled 
in a home oximetry programme across four pilot sites. 
Participants were excluded if primary care data and 
oxygen saturations at rest at enrolment were not available. 
Data from 908 participants were included in the analysis.
Interventions Home oximetry monitoring was provided 
to participants with a known or suspected diagnosis of 
COVID-19. Participants were enrolled following attendance 
to emergency departments, hospital admission or referral 
through primary care services.
Results Of 908 patients enrolled into four different 
COVID-19 home oximetry programmes in England, 771 
(84.9%) had oxygen saturations at rest of 95% or more, 
and 320 (35.2%) were under 65 years of age and without 
comorbidities. 52 (5.7%) presented to hospital and 28 
(3.1%) died following enrolment, of which 14 (50%) 
had COVID-19 as a named cause of death. All- cause 
mortality was significantly higher in patients enrolled after 
admission to hospital (OR 8.70 (2.53–29.89)), compared 
with those enrolled in primary care. Patients enrolled after 
hospital discharge (OR 0.31 (0.15–0.68)) or emergency 
department presentation (OR 0.42 (0.20–0.89)) were 
significantly less likely to present to hospital than those 
enrolled in primary care.
Conclusions This study finds that home oximetry 
monitoring can be a safe pathway for patients with 
COVID-19; and indicates increases in risk to vulnerable 
groups and patients with oxygen saturations <95% 
at enrolment, and in those enrolled on discharge from 
hospital. Findings from this evaluation have contributed 
to the national implementation of home oximetry across 
England.
INTRODUCTION
Before the outbreak of the COVID-19 
pandemic, compelling evidence already 
existed regarding the role of telemedicine 
and digital technologies in restructuring 
how healthcare is delivered, indicating an 
opportunity to expand the use of virtual 
pathways.1 Such evidence suggests that care 
delivered remotely can, in many circum-
stances, safely meet patients’ clinical needs 
and personal preferences.1–3 Specifically, 
remote monitoring pathways, those that rely 
on an initial point of contact with the health 
services followed by continuous monitoring 
via phone calls, digital or app- based diaries 
or wearable sensors, have also demonstrated 
effectiveness, especially when supported by 
behavioural change models.4–6 However, the 
clinical effectiveness, safety and economic 
utility of this type of monitoring are context 
dependent and vary considerably across clin-
ical conditions; therefore, more evidence is 
required to fully assess their impact.4
During the COVID-19 pandemic, the UK 
National Health Service (NHS), and health 
systems across the world, rapidly adopted 
novel remote monitoring pathways, many 
relying on home pulse oximetry.7–9 These 
Strengths and limitations of this study
 ► This multisite study examines outcomes and varia-
tion between four COVID-19 home oximetry remote 
monitoring pathways in England.
 ► It uses linked data from primary and secondary care, 
alongside mortality data and data collected from the 
oximetry pathway to understand clinical outcomes 
and prior risk factors.
 ► It examines the clinical status of patients enrolled 
under different home oximetry pathways and exam-
ines their rates of hospital attendance and all- cause 
mortality.
 ► The study is limited to four sites, and is unable to 
comment on the outcomes of patients not enrolled 
into these pathways or on the performance of path-
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pathways were often initiated quickly in an attempt to 
proactively manage patients without risking unnecessary 
patient travel to hospital, but subsequently varied in terms 
of the devices used, patients included and the method of 
implementation. The available literature suggests poten-
tial for home management of COVID-19 to support a 
positive patient experience.10–12 However, while pulse 
oximetry and trends over time appear to be an effective 
way of detecting deterioration, the evidence surrounding 
the safety of oximetry devices, specifically low- cost pocket 
oximeters, is variable and more research is required to 
understand what oxygen saturation thresholds should 
trigger a patient to seek in- person care.13 14 Overall, the 
literature surrounding whether home oximetry moni-
toring for patients with COVID-19 is safe remains incon-
clusive.9 15
In the UK, NHS England/Improvement, the body 
responsible for improved delivery of NHS care, in part-
nership with NHS Digital and Imperial College London, 
set out to understand, quantitatively, whether home oxim-
etry monitoring was a safe clinical pathway to implement 
nationally. Following the first UK peak of COVID-19, in 
Spring 2020, pilots of home oximetry monitoring tested a 
system- wide approach to the early detection of COVID-19 
in the community. As part of this pilot, a rapid evalua-
tion was conducted to determine whether home oximetry 
monitoring was a safe clinical pathway. Based on existing 
literature, the initial hypothesis was that early recogni-
tion, escalation, admission and treatment could save lives 
in COVID-19 and would be a safe approach to adopt. In 
December 2020, informed by the findings of this study, 
NHS England and NHS Improvement recommended 
that all Clinical Commissioning Groups put in place a 
COVID-19 home oximetry service. At the time of writing, 
more than 20 000 patients in England have been treated 
on similar pathways to those included in this study.16
Aims and objectives
This study aimed to answer the research question: are home 
oximetry monitoring pathways safe and effective for patients with 
COVID-19 in the English NHS?
The primary objective was to determine whether 
patients suffered any adverse consequences as a result 
of home oximetry monitoring. The secondary objective 
was to explore whether the recommendations relating 
to oxygen saturation that were published in June 2020 
in the NHS COVID-19 assessment pathway were correct. 
The final objective was to contribute to a recommenda-
tion to NHS England/Improvement regarding the safety 




To answer this question, Imperial College NHS Health-
care Trust, National Institute for Health Research Impe-
rial Patient Safety Translational Research Centre at the 
Institute of Global Health Innovation (IGHI) at Impe-
rial College London, working in partnership with NHS 
Digital, assessed existing evidence concerning home 
oximetry monitoring for respiratory conditions and anal-
ysed prospective data collected from four sites.
This was a retrospective, multisite, observational study 
of home oximetry monitoring for patients with suspected 
or proven COVID-19 in England during Summer 2020, 
including an analysis of patient data from four pilot sites: 
North West London, Slough, South Tees and Watford. 
Sites varied in how patients were enrolled onto pathways; 
from primary care, after a presentation to the emer-
gency department or following a hospital admission, or a 
combination of these. In each site, patients were enrolled 
onto the oximetry pathway and were provided with a 
pulse oximeter to measure their oxygen saturations and 
heart rate over time. These recordings, in addition to a 
patient’s symptoms and perceived overall well- being, were 
communicated to their nominated healthcare profes-
sional (either a general practitioner, practice nurse or 
hospital doctor) through a combination of app- based 
platforms and paper diaries. The frequency of recording 
varied between pathways, from daily to several times 
per day. In the case of clinical deterioration or other 
concerns, patients were able to contact their nominated 
healthcare professional for advice and escalation of care 
could be initiated as appropriate. While services may vary 
between sites, the current standard operating procedure 
for COVID-19 home oximetry services in England can be 
accessed on the NHS Digital website.17
Quantitative analysis was conducted in the IGHI’s Big 
Data and Analytical Unit (BDAU). The BDAU provides 
a fully certified ISO 27001:2013 research environment 
within Imperial College and is fully compliant with NHS 
IG Toolkit Level 3 (EE133887). Analysis took place within 
the Imperial College London BDAU.
Information and data
Four separate data sets linked by a pseudonymised patient 
identifier were provided by NHS Digital for the express 
purpose of this evaluation. A full list of variables collected 
is included in online supplemental file 1 and summarised 
below.
Primary care records
Data pertaining to patient demographics and clinical 
comorbidities were obtained from the General Practice 
Extraction Service Data for Pandemic Planning and 
Research (GDPPR) for all patients enrolled into a home 
oximetry monitoring programme at one of the four 
sites. Records were available from the start of a patient’s 
primary care record in the practice to the date of data 
transfer (25 September 2020).
Home oximetry monitoring records
For each patient enrolled into a home oximetry moni-
toring programme at the four sites, data were collected 
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consisting of the date of enrolment, oxygen saturations at 
rest at enrolment and the clinical pathway to which they 
were enrolled.
Hospital records
The dates, outcomes of accident and emergency (A&E) 
presentations and admissions to hospital for patients 
while enrolled in the home oximetry programme were 
obtained from case note review by participating sites. 
Data were returned by sites in mid- September 2020.
Mortality records
The date and causes (as International Classification of 
Diseases 10th Revision (ICD-10) codes) of death were 
provided for each patient whose death had been recorded 
by the Office for National Statistics after enrolment to the 
home oximetry programme until the date of data transfer 
(25 September 2020).
Analysis and statistical procedure
Data were linked according to the pseudonymised patient 
identifier. A single cohort of patients was identified where 
GDPPR data and oxygen saturations at rest at enrolment 
were available. The demographic and clinical character-
istics of this population were described and differences 
in patient and clinical characteristics were compared 
between routes of enrolment using pairwise Fisher’s exact 
tests for count data and Mann- Whitney U (MWU) tests 
for non- parametric continuous data.
The likelihood of a patient presenting to hospital at 
least once following enrolment to the home oximetry 
monitoring programme was examined using univariable 
and multivariable logistic regression models. The likeli-
hood of all- cause mortality following enrolment to the 
home oximetry monitoring programme was also exam-
ined using univariable and multivariable logistic regres-
sion models. Frequent absence of dates of enrolment or 
dates of hospital admission precluded formal temporal 
evaluation of time to hospital presentation or mortality.
RESULTS
A total of 1338 patients were recorded as being enrolled 
into the home oximetry programme at one of the four 
pilot sites. Of these, GDPPR records were available for 
1242 patients (92.8%). Of these patients, a recorded 
oxygen saturation level at enrolment onto the home 
oximetry was present for 908 patients (73.1%).
Comparison of enrolment pathways
The characteristics of the included population, overall 
and according to the route of enrolment, are described 
in table 1. Three hundred and two patients were enrolled 
from primary care (33.4%), 342 from A&E (37.9%) and 
259 following discharge from hospital (28.9%). Route of 
enrolment was missing for five patients (0.6%).
Oxygen saturations at enrolment were significantly 
lower in those enrolled on discharge from hospital (96%) 
than through A&E (97%) or primary care (98%) (MWU, 
p<0.001). No difference was observed between primary 
care and A&E pathways (MWU, p=0.085). Similarly, 
there was no significant difference in the proportion of 
patients enrolled with oxygen saturations of 95% or more 
in primary care (92.0%) or A&E (91.8%) (Fisher’s exact 
test, p=1.000); however, only 67.6% of patients enrolled 
after hospital discharge had oxygen saturations of 95% or 
more (pairwise Fisher’s exact tests, p<0.001).
Patients enrolled through A&E were most likely to have 
no comorbidities (47.1%) compared with primary care 
(37.4%) and hospital discharge (27.0%). Primary care 
patients were less likely to have comorbidities than those 
enrolled after hospital discharge (pairwise Fisher’s exact 
tests, p<0.05 in all cases). Patients enrolled through A&E 
were younger (median age=50 years) than those enrolled 
in primary care (55 years) and on hospital discharge (63 
years) (MWU, p<0.001 in all cases).
Presentation to hospital
A total of 69 presentations to hospital were made by 52 
patients (5.7%) after enrolment. Forty of these patients 
(76.9%) were admitted to hospital, and eight patients 
(15.4%) presented more than once. The proportion of 
patients presenting to hospital according to age group 
and number of clinical comorbidities is shown in figures 1 
and 2.
3.1% of patients under the age of 65 years and without 
comorbidities presented to hospital, compared with 5.0% 
of those under 65 with comorbidities and 9.7% of those 
aged 65 and over. Similarly, 5.3% of patients with oxygen 
saturations of 95% or more at enrolment presented to 
hospital, compared with 6.1% of those with oxygen satu-
rations of 93%–94% and 10.9% of those with oxygen satu-
rations less than 93% at enrolment (table 2).
In univariable logistic regression models, presentation 
to hospital was significantly more likely in older patients 
and those with more clinical comorbidities, while those 
initiated on the home oximetry through A&E or on 
discharge from hospital were less likely to re- present to 
hospital (table 3). In the multivariable model, increasing 
age (OR 1.03, p=0.018) was associated with significantly 
higher odds of presentation to hospital, while those initi-
ated through A&E (OR 0.42, p=0.024) and following 
discharge from hospital (OR 0.31, p=0.003) were signifi-
cantly less likely to present to hospital (table 3).
All-cause mortality
A total of 28 patients (3.1%) died of any cause following 
enrolment. Fourteen of these patients (50.0%) had 
COVID-19 as a named cause of death (ICD-10 code 
U07.1), and 12 (42.9%) had COVID-19 as the under-
lying cause of death. All- cause mortality by age group and 
number of clinical comorbidities is shown in figures 1 
and 2. Only patients with one or more comorbidities 
died, while 17 (60.1%) patients who died had four or 
more clinical comorbidities.
None of the 320 patients under the age of 65 and 
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Total patients 302 342 259 908
Female 180 (59.6) 205 (59.9) 120 (46.3) 508 (55.9)
Median age (years) 55 50 63 54
Ethnicity White 113 (37.4) 160 (46.8) 140 (54.1) 415 (45.7)
Black, Asian and 
minority Ethnic
82 (27.2) 103 (30.1) 59 (22.8) 244 (26.9)
Not recorded 107 (35.4) 79 (23.1) 60 (23.2) 249 (27.4)
Overweight or obese 108 (35.8) 189 (55.3) 160 (61.8) 458 (50.4)
Median oxygen saturations 98 97 96 97
Clinical severity based on 
oxygen saturations
Mild (≥95%) 278 (92.1) 314 (91.8) 175 (67.6) 771 (84.9)
Moderate (93%–
94%)
17 (5.6) 22 (6.4) 42 (16.2) 82 (9.0)
Severe (≤92%) 7 (2.3) 6 (1.8) 42 (16.2) 55 (6.1)
Clinical comorbidities (n) 0 113 (37.4) 161 (47.1) 70 (27.0) 346 (38.1)
1 75 (24.8) 105 (30.7) 70 (27.0) 252 (27.7)
2 42 (13.9) 45 (13.2) 44 (17.0) 131 (14.4)
3+ 72 (23.8) 31 (9.1) 75 (29.0) 179 (19.7)
Hypertension 102 (33.8) 65 (19.0) 111 (42.9) 278 (30.8)
Depression 86 (28.5) 84 (24.6) 72 (27.8) 242 (26.8)
Asthma 75 (24.8) 83 (24.3) 49 (18.9) 207 (22.9)
Steroid use 87 (28.8) 62 (18.1) 54 (20.8) 203 (22.5)
Diabetes mellitus 56 (18.5) 43 (12.6) 63 (24.3) 162 (17.9)
Pregnancy 37 (12.3) 74 (21.6) 23 (8.9) 134 (14.8)
Chronic heart disease 43 (14.2) 35 (10.2) 55 (21.2) 133 (14.7)
Mild frailty 41 (13.6) 17 (5.0) 42 (16.2) 100 (11.1)
Moderate frailty 45 (14.9) 8 (2.3) 43 (16.6) 96 (10.6)
Chronic respiratory disease 39 (12.9) 17 (5.0) 35 (13.5) 91 (10.1)
Chronic kidney disease 32 (10.6) 17 (5.0) 41 (15.8) 90 (10.0)
Cancer 32 (10.6) 23 (6.7) 23 (8.9) 78 (8.6)
Hypothyroidism 29 (9.6) 22 (6.4) 17 (6.6) 68 (7.5)
Hypercholesterolaemia 30 (9.9) 14 (4.1) 22 (8.5) 66 (7.3)
Chronic neurological disease 28 (9.3) 7 (2.0) 25 (9.7) 60 (6.6)
Severe frailty * * * 53 (5.9)
Stroke * * * 46 (5.1)
Immunosuppression drug 8 (2.6) 12 (3.5) 7 (2.7) 27 (3.0)
Dementia * * * 25 (2.8)
Mental illness 8 (2.6) 6 (1.8) 8 (3.1) 22 (2.4)
Epilepsy * * * 20 (2.2)
Peripheral vascular disease * * * 13 (1.4)
Autoimmune disease * * * 13 (1.4)
Chronic liver disease * * * 9 (1.0)
Learning disability * * * 6 (0.7)
Route of enrolment was missing for 5 of 908 patients. Comorbidity case numbers are shown with an asterisk (*) for routes of enrolment where 
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the study period, compared with 0.9% of those under 65 
with comorbidities and 9.3% of those aged 65 and over. 
2.6% of patients with oxygen saturations of 95% or more 
at enrolment died during the study period, compared with 
6.1% of those with oxygen saturations of 93%–94% and 
5.5% of those with oxygen saturations less than 93% at 
enrolment (table 2).
In univariable logistic regression models, all- cause 
mortality was significantly more likely in older patients, 
those of black, Asian and minority ethnic ethnicity, with 
more clinical comorbidities, who were overweight or 
obese and those initiated on the home oximetry following 
discharge from hospital (table 4). In the multivariable 
model, increasing age (OR 1.08, p < 0.001), more clin-
ical comorbidities (OR 1.45, p=0.009), being overweight 
or obese (OR 4.83, p=0.002) and being initiated on the 
home oximetry following discharge from hospital (OR 
8.70, p=0.001) were associated with significantly higher 
odds of all- cause mortality (table 4).
DISCUSSION
Statement of key findings
In terms of clinical safety, only 5.7% of patients presented 
to hospital after enrolment. The likelihood of presenting 
to hospital increased with age, but was not significantly 
associated with ethnicity, number of clinical comor-
bidities, obesity or oxygen saturations at enrolment. 
However, all- cause mortality was significantly more likely 
with increasing age, number of clinical comorbidities 
and obesity. All- cause mortality was also higher for those 
patients who initiated the pathway after discharge from 
hospital. Finally, most patients using home oximetry 
monitoring were of low clinical severity on initiation and 
neither died nor presented to hospital during the study 
period. Therefore, the COVID-19 assessment pathway 
published in June 2020 is clinically appropriate, and its 
recommendations regarding oxygen saturation thresh-
olds are correct.
While hospital presentation and mortality were associ-
ated with lower oxygen saturations at enrolment, this was 
not a statistically significant relationship after controlling 
for other patient factors. Therefore, although oxygen 
saturation at enrolment may provide an important tool 
by which to stratify clinical severity, such assessments 
must also incorporate a wider understanding of factors 
determining outcome including age, obesity and clinical 
comorbidities.
None of the 320 participants aged less than 65 and 
without comorbidities died during the study period. 
These individuals accounted for 33.3% of all participants 
which suggests that during the pilots a large proportion 
of the participants were low risk at enrolment and did 
not suffer any adverse outcome. Wider implementation 
should therefore focus on higher risk groups to ensure 
efficient use of limited health and care resources.
Statistically significant variation in the characteristics 
of patients, clinical severity of illness, rates of hospital 
presentation and all- cause mortality were observed 
between the three routes of enrolment. Patients enrolled 
following a hospital admission had 8.7 times higher odds 
of all- cause mortality than patients enrolled in primary 
care after adjusting for age, sex, ethnicity, obesity, clin-
ical comorbidities and oxygen saturation at enrolment. 
Conversely, compared with those enrolled in primary 
care, patients enrolled after an A&E presentation or 
hospital admission had significantly lower odds of further 
presentation to hospital after enrolment. Collectively, this 
indicates differences in patient characteristics and the risk 
of adverse events according to the route of enrolment. 
Those enrolled in primary care are generally the least 
unwell and go on to have lower rates of hospital presenta-
tion and mortality. The finding that patients enrolled in 
A&E or following hospital admission have lower rates of 
hospital presentation may indicate reluctance on the part 
Figure 1 Percentage all- cause mortality and presentation to 
hospital according to patient age.
Figure 2 Percentage all- cause mortality and presentation to 
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of patients to return to hospital during the same period 
of illness. Patients enrolled following hospital discharge 
appear to be at particularly high risk of mortality and 
may therefore represent a patient population that should 
either be offered more intensive monitoring or alternative 
approaches to reducing the risk of subsequent mortality.
Following enrolment more patients aged 90 years and 
over died during the study period than presented to 
hospital, while in younger age groups hospital presen-
tations outnumbered all- cause mortality (figure 1). A 
similar trend was observed according to increasing clin-
ical comorbidities (figure 2). This is likely to reflect 
circumstances in which hospital admission is not in accor-
dance with a patient’s wishes or considered clinically 
appropriate, and end- of- life care is therefore initiated in 
a person’s usual place of residence.
Taken together, our results support the hypothesis 
that oximetry monitoring is a safe pathway for patients 
with COVID-19. This was reported to NHS England and 
Improvement in October 2020.
Strengths and limitations
The primary strength of this study is its system- level and 
patient- level impact, since this work evaluated a real- world 










Total patients ≥65 years 203 (75.5) 37 (13.8) 29 (10.8) 269 (29.6)
<65 years with comorbidities 277 (86.8) 29 (9.1) 13 (4.1) 319 (35.1)
<65 years without comorbidities 291 (90.9) 16 (5.0) 13 (4.1) 320 (35.2)
Overall 771 (84.9) 82 (9.0) 55 (6.1) 908 (100.0)
Hospital presentation ≥65 years 18 (8.9) 3 (8.1) 5 (17.2) 26 (9.7)
<65 years with comorbidities 13 (4.7) 2 (6.9) 1 (7.7) 16 (5.0)
<65 years without comorbidities 10 (3.4) 0 (0.0) 0 (0.0) 10 (3.1)
Overall 41 (5.3) 5 (6.1) 6 (10.9) 52 (5.7)
All- cause mortality ≥65 years 18 (8.9) 4 (10.8) 3 (10.3) 25 (9.3)
<65 years with comorbidities 2 (0.7) 1 (3.4) 0 (0.0) 3 (0.9)
<65 years without comorbidities 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Overall 20 (2.6) 5 (6.1) 3 (5.5) 28 (3.1)
Table 3 Univariable and multivariable binary logistic regression output for presentation to hospital following enrolment to the 
home oximetry pathway
Univariable Multivariable
OR P value 95% CI of OR OR P value 95% CI of OR
Age 1.03 < 0.001 1.01 to 1.05 1.03 0.018 1.00 to 1.05
Ethnicity White Reference Reference
Black, Asian and 
minority ethnic
1.22 0.544 0.64 to 2.32 1.57 0.198 0.79 to 3.10
Not recorded 0.75 0.447 0.36 to 1.57 0.95 0.912 0.42 to 2.17
Number of comorbidities 1.25 0.004 1.08 to 1.45 1.07 0.503 0.88 to 1.30
Overweight or obese 0.67 0.175 0.38 to 1.19 0.55 0.069 0.29 to 1.05
Clinical severity 
based on oxygen 
saturations
Mild (≥95%) Reference Reference
Moderate (93%–
94%)
1.16 0.766 0.44 to 3.01 1.08 0.885 0.40 to 2.92
Severe (≤92%) 2.18 0.091 0.88 to 5.39 2.35 0.096 0.86 to 6.46
Enrolment 
pathway
Primary care Reference Reference
Accident and 
emergency
0.37 0.005 0.18 to 0.74 0.42 0.024 0.20 to 0.89
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pilot of a new clinical pathway. The project team achieved 
an integrated partnership between academics, clinicians 
and policymakers. This enabled a direct pipeline from 
evidence generation to policy decision- making; more-
over, the efficiency with which the work was conducted 
was nationally important, as it was required to inform how 
the NHS would use home oximetry monitoring during 
the next wave of the pandemic. Impact was achieved 
through the unique composition of the evaluation team 
as well as the close relationship the team held to NHS 
leaders in home oximetry monitoring. The method for 
this work required novel data reporting from the pilot 
sites to the evaluation team and this was ensured through 
close collaboration with the individual sites.
The most prevalent limitation related to data quality 
and completeness. The pilot sites varied in their routes 
of referral and in the clinical severity of the patients 
they enrolled. Furthermore, there was heterogeneity 
in the actual intervention across the sites, as some 
enrolled patients with suspected COVID-19, while others 
included patients who had received hospital treatment 
for COVID-19 and were subsequently discharged. Due 
to the rapid timescales of this evaluation and the pres-
sured environment in which it took place, mandating 
full completeness in the data submitted was not possible, 
and the resulting data set had a considerable amount of 
missing data. The lack of longitudinal oxygen saturation 
data precluded temporal analysis of patient trajectories 
and identification of deterioration in clinical status. 
While such an evaluation would have been valuable, it 
was not possible within the available data set. In addition 
to oxygen saturations, other physiological parameters, in 
including respiratory rate, may be important indicators of 
clinical severity in patients with COVID-19.18 In this study, 
only oxygen saturations were available which precluded 
analysis of clinical severity according to a broader range 
of physiological parameters.
In addition, the absence of precise temporal recording 
of data and an inability to complete individual case note 
reviews precluded a more detailed evaluation of whether 
deaths occurred as a result of COVID-19 infection, or 
another cause entirely. Finally, this was not a controlled 
study, which prevented a comparative analysis. Due to 
these limitations and the relatively low community prev-
alence of COVID-19 during the pilot, our findings are 
not necessarily generalisable to future waves of COVID-
19. Additionally, while many initial oxygen saturations 
are likely to be taken in the presence of a healthcare 
professional, we are unable to determine whether these 
readings are taken correctly and may therefore provide 
inappropriate estimates of clinical acuity.
Comparison to other studies
While research evidence regarding COVID-19 home 
oximetry is still in its infancy, this study reflects similar 
findings in the published literature. One systematic 
review of home monitoring for COVID-19 acknowledges 
inconclusive evidence about effectiveness and safety. 
While this study could not conclusively determine the 
clinical effectiveness of the pilots, it was able to demon-
strate non- inferiority in terms of safety with traditional 
hospital management of COVID-19.
Furthermore, this study indicates the potential for these 
technologies to support pandemic management in line 
with expert opinions published in the literature.19 The 
findings of this work are consistent with existing grey liter-
ature suggesting the utility of home oximetry monitoring 
for COVID-19.8 20 This study specifically assessed the safety 
of home oximetry for COVID-19 and makes policy recom-
mendations not present in existing studies which tend to 
Table 4 Univariable and multivariable binary logistic regression output for all- cause mortality following enrolment to the home 
oximetry pathway
Univariable Multivariable
OR P value 95% CI of OR OR P value 95% CI of OR
Age 1.12 <0.001 1.08 to 1.16 1.08 <0.001 1.03 to 1.13
Ethnicity White Reference Reference
Black, Asian and 
minority Ethnic
0.16 0.015 0.04 to 0.70 0.37 0.235 0.07 to 1.90
Not recorded 0.49 0.129 0.19 to 1.23 0.61 0.371 0.21 to 1.79
Number of comorbidities 1.97 <0.001 1.63 to 2.40 1.45 0.009 1.09 to 1.92





Mild (≥95%) Reference Reference
Moderate (93%–94%) 2.43 0.083 0.89 to 6.68 1.11 0.864 0.34 to 3.67
Severe (≤92%) 2.16 0.224 0.62 to 7.53 0.65 0.574 0.14 to 2.93
Enrolment 
pathway
Primary care Reference Reference
Accident and 
emergency
0.66 0.587 0.15 to 2.97 3.40 0.157 0.62 to 18.55
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focus more on patient experience and potential clinical 
effectiveness. These findings echo the findings of a previous 
systematic review indicating a paucity of studies directly 
addressing patient safety in telemedicine.21 Identifying the 
potential patient safety risks arising from the national home 
oximetry programme is an area of ongoing qualitative and 
quantitative research as part of the national COVID-19 
Oximetry at Home Programme.20
Implications for policy
This work was explicitly designed to answer relevant ques-
tions in advance of the national implementation of a new 
clinical pathway for COVID-19. It confirms the appro-
priateness of existing policies and that safety netting 
approaches are congruent with findings.
This study provides information as to how the pathway 
should function including the thresholds at which people 
should be enrolled into home oximetry monitoring 
programmes, how long they should continue in home oxim-
etry monitoring and what sorts of technology are required 
to support home oximetry monitoring for COVID-19.
Furthermore, the practicalities of running this study 
revealed important considerations for the ongoing evalu-
ation of home oximetry monitoring pathways for COVID-
19. It is clear from the study that it is only possible to 
measure the safety of home oximetry monitoring with the 
robust and rigorous collection of data from healthcare 
providers as well as any third party app- based providers. 
This data flow should continue during national imple-
mentation to continuously measure safety under different 
conditions and levels of organisational pressure.
CONCLUSION
Advancing the evidence base regarding the safety of 
home oximetry monitoring for patients with COVID-19 
is of considerable importance as many health systems 
face new waves of the pandemic worldwide. This study 
reveals, via a real- world pilot evaluation, that home oxim-
etry monitoring can be a safe pathway for patients with 
COVID-19; however, substantial research is needed to 
understand its clinical effectiveness across patient popula-
tions. This study was limited by complex and incomplete 
data as well as variation in intervention designs; a product 
of the pandemic context within which it was undertaken. 
However, it did provide initial evidence of the appropriate 
clinical thresholds and patient characteristics for home 
oximetry. It also indicated increases in risk to vulnerable 
groups and patients with oxygen saturations below 95% 
at enrolment.
Findings from this evaluation have contributed to 
the national implementation of home oximetry across 
England, and further work will be undertaken to eval-
uate clinical effectiveness and any inequalities in terms of 
access to, and inclusion in, the new pathway.
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